​

RAPT Therapeutics (RAPT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

RAPT Stock Forecast

RAPT Therapeutics (RAPT) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $52.71, with a high of $70.00 and a low of $9.00. This represents a -8.57% decline from the last price of $57.65.

- $14 $28 $42 $56 $70 High: $70 Avg: $52.71 Low: $9 Last Closed Price: $57.65

RAPT Stock Rating

RAPT Therapeutics stock's rating consensus is Hold, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (26.67%), 11 Hold (73.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 15 0 11 4 Strong Sell Sell Hold Buy Strong Buy

RAPT Price Target Upside V Benchmarks

TypeNameUpside
StockRAPT Therapeutics-8.57%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts6712
Avg Price Target$64.17$65.29$56.67
Last Closing Price$57.65$57.65$57.65
Upside/Downside11.31%13.25%-1.70%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 26271--10
Dec, 25261--9
Nov, 25351--9
Oct, 25133--7
Sep, 25124--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 21, 2026Barclays$58.00$57.590.71%0.61%
Jan 21, 2026Thomas SmithLeerink Partners$58.00$57.570.75%0.61%
Jan 20, 2026Yanan ZhuWells Fargo$58.00$57.500.87%0.61%
Jan 20, 2026Emily BodnarH.C. Wainwright$58.00$57.510.85%0.61%
Jan 20, 2026Piper Sandler$58.00$57.520.83%0.61%
Jan 09, 2026Piper Sandler$95.00$31.20204.49%64.79%
Nov 03, 2025Wells Fargo$72.00$30.21138.33%24.89%
Oct 27, 2025H.C. Wainwright$72.00$30.03139.76%24.89%
Oct 27, 2025Yatin SunejaGuggenheim$70.00$29.53137.05%21.42%
Oct 13, 2025Barclays$35.00$26.7930.65%-39.29%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 21, 2026Leerink PartnersMarket PerformMarket Performdowngrade
Jan 20, 2026Cowen & Co.BuyHolddowngrade
Jan 20, 2026H.C. WainwrightBuyNeutraldowngrade
Jan 20, 2026GuggenheimBuyNeutraldowngrade
Jan 20, 2026Piper SandlerOverweightNeutraldowngrade
Jan 09, 2026Piper SandlerOverweightOverweightinitialise
Dec 18, 2025Cowen & Co.Buyinitialise
Oct 27, 2025H.C. WainwrightBuyBuyhold
Oct 27, 2025GuggenheimNeutralBuyinitialise
Oct 21, 2025Wells FargoOverweightOverweighthold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.49$-2.52$-3.05$-3.19----
Avg Forecast$-2.57$-2.56$-3.11$-2.13$-0.85$-1.07$-1.13$-1.29
High Forecast$-2.57$-2.56$-3.04$-2.06$-0.57$-0.21$-1.13$-1.29
Low Forecast$-2.57$-2.56$-3.17$-2.25$-1.27$-1.92$-1.13$-1.29
Surprise %-3.11%-1.56%-1.93%49.77%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.81M$1.53M------
Avg Forecast$3.89M$1.69M--$768.35K$10.19M$101.25M$83.70M
High Forecast$3.89M$1.69M--$768.35K$10.19M$101.25M$83.70M
Low Forecast$3.89M$1.69M--$768.35K$10.19M$101.25M$83.70M
Surprise %-1.86%-9.58%------

Net Income Forecast

$-150M $-120M $-90M $-60M $-30M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-68.21M$-81.88M$-116.80M$-129.87M----
Avg Forecast$-98.68M$-98.13M$-116.80M$-82.56M$-35.15M$-40.96M$-43.32M$-49.46M
High Forecast$-98.68M$-98.13M$-116.56M$-79.03M$-21.76M$-8.13M$-43.32M$-49.46M
Low Forecast$-98.68M$-98.13M$-121.56M$-86.09M$-48.54M$-73.80M$-43.32M$-49.46M
Surprise %-30.88%-16.56%-57.30%----

RAPT Forecast FAQ

Is RAPT Therapeutics stock a buy?

RAPT Therapeutics stock has a consensus rating of Hold, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 11 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that RAPT Therapeutics is a neutral investment for most analysts.

What is RAPT Therapeutics's price target?

RAPT Therapeutics's price target, set by 15 Wall Street analysts, averages $52.71 over the next 12 months. The price target range spans from $9 at the low end to $70 at the high end, suggesting a potential -8.57% change from the previous closing price of $57.65.

How does RAPT Therapeutics stock forecast compare to its benchmarks?

RAPT Therapeutics's stock forecast shows a -8.57% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for RAPT Therapeutics over the past three months?

  • January 2026: 20.00% Strong Buy, 70.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is RAPT Therapeutics’s EPS forecast?

RAPT Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.85, marking a -73.35% decrease from the reported $-3.19 in 2024. Estimates for the following years are $-1.07 in 2026, $-1.13 in 2027, and $-1.29 in 2028.

What is RAPT Therapeutics’s revenue forecast?

RAPT Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $768.35K, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $10.19M, followed by $101.25M for 2027, and $83.7M for 2028.

What is RAPT Therapeutics’s net income forecast?

RAPT Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-35.151M, representing a -72.93% decrease from the reported $-130M in 2024. Projections indicate $-40.962M in 2026, $-43.322M in 2027, and $-49.456M in 2028.